Raymond James Financial Services Advisors’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $4.02M | Sell |
25,924
-2,002
| -7% | -$299K | 0.01% | 1349 |
|
|
2024
Q2 | $3.82M | Sell |
27,926
-31,933
| -53% | -$4.37M | 0.01% | 1303 |
|
|
2024
Q1 | $7.97M | Buy |
59,859
+2,807
| +5% | +$364K | 0.01% | 915 |
|
|
2023
Q4 | $7.87M | Buy |
57,052
+5,173
| +10% | +$680K | 0.01% | 866 |
|
|
2023
Q3 | $6.32M | Sell |
51,879
-510
| -1% | -$68K | 0.01% | 898 |
|
|
2023
Q2 | $7.36M | Sell |
52,389
-19,807
| -27% | -$2.73M | 0.01% | 836 |
|
|
2023
Q1 | $10.2M | Buy |
72,196
+24,440
| +51% | +$3.5M | 0.02% | 682 |
|
|
2022
Q4 | $7.47M | Sell |
47,756
-3,396
| -7% | -$488K | 0.02% | 781 |
|
|
2022
Q3 | $6.28M | Sell |
51,152
-1,291
| -2% | -$170K | 0.01% | 817 |
|
|
2022
Q2 | $6.97M | Sell |
52,443
-3,775
| -7% | -$514K | 0.02% | 774 |
|
|
2022
Q1 | $7.7M | Sell |
56,218
-12,670
| -18% | -$1.77M | 0.01% | 797 |
|
|
2021
Q4 | $11.9M | Buy |
68,888
+3,000
| +5% | +$456K | 0.02% | 616 |
|
|
2021
Q3 | $9.58M | Buy |
65,888
+1,460
| +2% | +$214K | 0.02% | 672 |
|
|
2021
Q2 | $8.5M | Sell |
64,428
-4,533
| -7% | -$593K | 0.02% | 730 |
|
|
2021
Q1 | $8.85M | Buy |
68,961
+18,195
| +36% | +$2.24M | 0.02% | 670 |
|
|
2020
Q4 | $6.05M | Buy |
50,766
+10,353
| +26% | +$1.26M | 0.02% | 752 |
|
|
2020
Q3 | $4.63M | Buy |
40,413
+1,525
| +4% | +$180K | 0.01% | 790 |
|
|
2020
Q2 | $4.43M | Buy |
38,888
+397
| +1% | +$42.1K | 0.01% | 751 |
|
|
2020
Q1 | $3.09M | Buy |
38,491
+10,611
| +38% | +$1.1M | 0.01% | 698 |
|
|
2019
Q4 | $2.98M | Buy |
27,880
+2,075
| +8% | +$216K | 0.01% | 975 |
|
|
2019
Q3 | $2.76M | Buy |
25,805
+280
| +1% | +$28.7K | 0.01% | 944 |
|
|
2019
Q2 | $2.6M | Buy |
25,525
+4,622
| +22% | +$444K | 0.01% | 958 |
|
|
2019
Q1 | $1.88M | Buy |
20,903
+7,165
| +52% | +$621K | 0.01% | 1103 |
|
|
2018
Q4 | $1.14M | Sell |
13,738
-163
| -1% | -$15.3K | 0.01% | 1188 |
|
|
2018
Q3 | $1.5M | Buy |
13,901
+1,373
| +11% | +$151K | 0.01% | 1224 |
|
|
2018
Q2 | $1.38M | Sell |
12,528
-375
| -3% | -$39.1K | 0.01% | 1231 |
|
|
2018
Q1 | $1.29M | Sell |
12,903
-3,146
| -20% | -$322K | 0.01% | 1163 |
|
|
2017
Q4 | $1.58M | Buy |
16,049
+27
| +0.2% | +$2.56K | 0.01% | 1018 |
|
|
2017
Q3 | $1.5M | Sell |
16,022
-753
| -4% | -$79.9K | 0.01% | 1063 |
|
|
2017
Q2 | $1.86M | Buy |
16,775
+1,109
| +7% | +$117K | 0.01% | 919 |
|
|
2017
Q1 | $1.54M | Sell |
15,666
-1,249
| -7% | -$119K | 0.01% | 949 |
|
|
2016
Q4 | $1.55M | Sell |
16,915
-986
| -6% | -$85K | 0.01% | 889 |
|
|
2016
Q3 | $1.51M | Sell |
17,901
-1,277
| -7% | -$107K | 0.01% | 881 |
|
|
2016
Q2 | $1.56M | Sell |
19,178
-1,132
| -6% | -$86.2K | 0.02% | 843 |
|
|
2016
Q1 | $1.45M | Buy |
+20,310
| New | +$1.36M | 0.02% | 753 |
|
Other funds holding DGX
DSA
Raymond James Financial Services Advisors's DGX Position: Q3 2024 in Review
Raymond James Financial Services Advisors reduced its Quest Diagnostics (DGX) stake by 7.2% in Q3 2024, selling an estimated $299K and leaving 25,924 shares worth $4.02M. The position accounts for 0.01% of the portfolio, ranked #1349.
Raymond James Financial Services Advisors first reported a position in DGX in Q1 2016 and has held it in 35 quarters since. The position peaked at $11.9M in Q4 2021. 847 funds tracked by Wall St. Rank hold DGX as of Q3 2024.
- Raymond James Financial Services Advisors held 25,924 shares of Quest Diagnostics worth $4.02M as of Q3 2024.
- Raymond James Financial Services Advisors sold 2,002 Quest Diagnostics shares in Q3 2024, an estimated $299K.
- Quest Diagnostics made up 0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #1349 holding.
- Raymond James Financial Services Advisors first reported a position in Quest Diagnostics in Q1 2016 and has held it in 35 quarters since.
- Raymond James Financial Services Advisors's Quest Diagnostics position peaked at $11.9M in Q4 2021.
- 847 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2024.
Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.